The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Emerging treatments for patients with CLL previously exposed to BTK inhibitors and venetoclax
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving treatment landscape for patients with chronic lymphocytic lymphoma (CLL) who have received prior BTK inhibitor and venetoclax therapy, highlighting the potential of non-covalent BTK inhibitors and degraders as next-line therapies. Dr Davids also discusses the potential of immune-based therapies, including epcoritamab and suravatamig bispecifics, in earlier lines of therapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
